CO5190714A1 - PHOSPHATE TRANSPORTATION INHIBITORS - Google Patents

PHOSPHATE TRANSPORTATION INHIBITORS

Info

Publication number
CO5190714A1
CO5190714A1 CO00053928A CO00053928A CO5190714A1 CO 5190714 A1 CO5190714 A1 CO 5190714A1 CO 00053928 A CO00053928 A CO 00053928A CO 00053928 A CO00053928 A CO 00053928A CO 5190714 A1 CO5190714 A1 CO 5190714A1
Authority
CO
Colombia
Prior art keywords
ammonium
sulfonyl
group
sulphonyl
alkylsulfonyl
Prior art date
Application number
CO00053928A
Other languages
Spanish (es)
Inventor
Joseph Winstock
Richard M Edwards
Dimitri Gaitanopoulo
Robert G Franz
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5190714A1 publication Critical patent/CO5190714A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un método para inhibir el transporte de fosfato dependiente del sodio, por medio de administrar a un sujeto que lo necesite, una cantidad segura y efectiva de un compuesto de acuerdo con la fórmula (I):<EMI FILE="00053928_1" ID="1" IMF=JPEG >donde:R1 y R2 se seleccionan independientemente del grupo constituido por hidrógeno, alquilo, alquenilo, arilalquilo, acilo, aroilo, haloalquilo, halo, carboxi, carboalcoxi, carbamoilo, alquilcarbamoilo, arilcarbamoilo, ciano, alcoxi, hidroxilo, fenilazo, amino, nitro, alquilamino, arilamino, arilalquilamino, acilamino, aroilamino, alquiltio, arilalquiltio, ariltio, alquisulfinilo, arilsulfinilo, arilalquilsulfinilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo, sulfamoilo, arilsulfonamido, y alquilsulfonamido;o el resto R1 representa un anillo condensado que forma un benzotiofeno, naftaleno, quinolina, o isoquinolina con el anillo del que es sustituyente;o (R1)n y el anillo del que es sustituyente, representa un heterociclo seleccionado del grupo constituido por tiofeno, furano, piridina, pirimidina, y pirazina, y sus benzo-análogos; yR3 se selecciona independientemente del grupo constituido por alquilo, haloalquilo, R1-arilo y R1-aralquilo, y heterociclos sustituidos con R1 seleccionados del grupo constituido por tionfeno, furano, piridina, pirimidina, pirazina, imidazol, y tiazol, y sus benzo-análogos. Un método para producir la excreción de fosfato y/o para inhibir la absorción de fosfato, por medio de administrar a un sujeto que lo necesite, una cantidad segura y efectiva de un compuesto de acuerdo con la fórmula (I):<EMI FILE="00053928_2" ID="2" IMF=JPEG >donde:R1 y R2 se seleccionan independientemente del grupo constituido por hidrógeno, alquilo, alquenilo, arilalquilo, acilo, aroilo, haloalquilo, halo, carboxi, carboalcoxi, carbamoilo, alquilcarbamoilo, arilcarbamoilo, ciano, alcoxi, hidroxilo, fenilazo, amino, nitro, alquilamino, arilamino, arilalquilamino, acilamino, aroilamino, alquiltio, arilalquiltio, ariltio, alquisulfinilo, arilsulfinilo, arilalquilsulfinilo, alquilsulfonilo, arilsulfonilo, arilalquilsulfonilo, sulfamoilo, arilsulfonamido, y alquilsulfonamido; ...A method to inhibit sodium dependent phosphate transport, by administering to a subject in need, a safe and effective amount of a compound according to formula (I): <EMI FILE = "00053928_1" ID = " 1 "MFI = JPEG> where: R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, acyl, aroyl, haloalkyl, halo, carboxy, carboalkoxy, carbamoyl, alkylcarbamoyl, arylcarbamoyl, cyano, alkoxy, hydroxyl, phenylazo, amino, nitro, alkylamino, arylamino, arylalkylamino, acylamino, aroylamino, alkylthio, arylalkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylalkylsulfinyl, alkylsulfonyl, arylsulfonyl, arylalkyl sulfonyl, sulfamoyl, sulfonamide, arylsulfonamide forms a benzothiophene, naphthalene, quinoline, or isoquinoline with the ring of which it is a substituent; or (R1) n and the ring of which it is a substituent, represents a selected heterocycle from the group consisting of thiophene, furan, pyridine, pyrimidine, and pyrazine, and their benzo-analogs; and R3 is independently selected from the group consisting of alkyl, haloalkyl, R1-aryl and R1-aralkyl, and R1 substituted heterocycles selected from the group consisting of thionphene, furan, pyridine, pyrimidine, pyrazine, imidazole, and thiazole, and their benzo-analogs . A method for producing phosphate excretion and / or for inhibiting phosphate absorption, by administering to a subject in need, a safe and effective amount of a compound according to formula (I): <EMI FILE = "00053928_2" ID = "2" MFI = JPEG> where: R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, alkenyl, arylalkyl, acyl, aroyl, haloalkyl, halo, carboxy, carboalkoxy, carbamoyl, alkylcarbamoyl, arylcarbamoyl, cyano, alkoxy, hydroxy, phenylazo, amino, nitro, alkylamino, arylamino, arylalkylamino, acylamino, aroylamino, alkylthio, arylalkylthio, arylthio, alkylsulfinyl, arylsulfinyl, arylalkylsulfinyl, alkylsulfonyl, arylsulfonyl, arylalkylsulfonyl, alkylsulfonyl, alkylsulfonyl ammonium ammonium ammonium sulfonammonium ammonium sulfonyl ammonium ammonium alkyl ammonium sulfonyl ammonium ammonium sulfonamylsulfonyl ammonium ammonium sulfonyl ammonium ammonium sulphonyl ammonium ammonium sulphonyl ammonium ammonium sulfonyl ammonium ammonium sulphonyl ammonium sulphonyl ammonium sulphonyl ammonium ammonium compounds ...

CO00053928A 1999-07-20 2000-07-18 PHOSPHATE TRANSPORTATION INHIBITORS CO5190714A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14464699P 1999-07-20 1999-07-20

Publications (1)

Publication Number Publication Date
CO5190714A1 true CO5190714A1 (en) 2002-08-29

Family

ID=22509500

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00053928A CO5190714A1 (en) 1999-07-20 2000-07-18 PHOSPHATE TRANSPORTATION INHIBITORS

Country Status (19)

Country Link
EP (1) EP1202729A1 (en)
JP (1) JP2003504403A (en)
KR (1) KR20020015382A (en)
CN (1) CN1361687A (en)
AR (1) AR030911A1 (en)
AU (1) AU6354300A (en)
BR (1) BR0012568A (en)
CA (1) CA2379657A1 (en)
CO (1) CO5190714A1 (en)
CZ (1) CZ2002204A3 (en)
HU (1) HUP0202938A3 (en)
IL (1) IL147697A0 (en)
MX (1) MXPA02000753A (en)
NO (1) NO20020278L (en)
NZ (1) NZ516619A (en)
PL (1) PL353741A1 (en)
TR (1) TR200200112T2 (en)
WO (1) WO2001005398A1 (en)
ZA (1) ZA200200464B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL359931A1 (en) * 2000-05-12 2004-09-06 Smithkline Beecham Corporation Phosphate transport inhibitors
GB2378179A (en) * 2001-08-03 2003-02-05 Pantherix Ltd Aromatic sulfonamides and their use in treating bacterial diseases
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7119120B2 (en) * 2001-12-26 2006-10-10 Genzyme Corporation Phosphate transport inhibitors
US7582673B2 (en) 2004-10-21 2009-09-01 High Point Pharmaceuticals, Llc Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use
WO2006077901A1 (en) * 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf expression inhibitor
JP2011523655A (en) * 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー Pharmaceutical composition comprising a gamma secretase modulator
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103819403B (en) 2008-12-31 2017-01-04 阿德利克斯公司 For treating the disease relevant with fluid retention or salt over loading and the Compounds and methods for of disorder of gastrointestinal tract
US8664425B2 (en) * 2010-02-02 2014-03-04 Honeywell International Inc. Bluegreen fluorescent compounds
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
WO2012054110A2 (en) 2010-07-07 2012-04-26 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
JP5827326B2 (en) * 2010-07-07 2015-12-02 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
WO2012006477A1 (en) 2010-07-07 2012-01-12 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2880338A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CN103183623A (en) * 2013-03-12 2013-07-03 中国医学科学院医药生物技术研究所 A group of benzene sulfonamido benzamide derivatives, and preparation and application thereof
EP2983667B1 (en) 2013-04-12 2019-03-20 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
CN105395532B (en) * 2015-11-25 2017-11-14 中国医学科学院医药生物技术研究所 Application of the 2 benzene sulfonamido benzamide compounds in liver injury protection and liver fibrosis preventing and treating
JP6713051B2 (en) * 2016-08-30 2020-06-24 日本曹達株式会社 Sulfonylaminobenzamide compounds and pest control agents
CN118221656A (en) 2017-01-09 2024-06-21 阿德利克斯股份有限公司 Compounds useful for the treatment of gastrointestinal disorders
BR112019013963A2 (en) 2017-01-09 2020-04-28 Ardelyx Inc nhe-mediated antiport inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86462A (en) * 1987-05-29 1992-12-01 Fujisawa Pharmaceutical Co Alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists

Also Published As

Publication number Publication date
HUP0202938A2 (en) 2003-01-28
CA2379657A1 (en) 2001-01-25
NZ516619A (en) 2004-02-27
IL147697A0 (en) 2002-08-14
BR0012568A (en) 2002-04-30
MXPA02000753A (en) 2002-07-22
ZA200200464B (en) 2003-04-30
KR20020015382A (en) 2002-02-27
AU6354300A (en) 2001-02-05
NO20020278D0 (en) 2002-01-18
NO20020278L (en) 2002-01-18
TR200200112T2 (en) 2002-05-21
PL353741A1 (en) 2003-12-01
EP1202729A1 (en) 2002-05-08
JP2003504403A (en) 2003-02-04
CN1361687A (en) 2002-07-31
WO2001005398A1 (en) 2001-01-25
CZ2002204A3 (en) 2002-11-13
HUP0202938A3 (en) 2006-07-28
AR030911A1 (en) 2003-09-03

Similar Documents

Publication Publication Date Title
CO5190714A1 (en) PHOSPHATE TRANSPORTATION INHIBITORS
AR043038A1 (en) PIRAZOLOTRIAZINE COMPOUNDS AND USES OF THE SAME
TR200101893T2 (en) 4-oxo-1,4 dihydro -3-quinolinecarboxamides as antiviral agents.
CO5460265A1 (en) CHEMICAL COMPOUNDS
PE20001484A1 (en) DERIVATIVES OF NAFTALEN-1-ILO UREA AND CARBAMIC ACID
PE20030200A1 (en) BENZHIMIDAZOLE AS INHIBITORS OF MAP KINASES
ES2189502T3 (en) METHOD FOR THE PREVENTION OF CITALOPRAM.
DE3373306D1 (en) Succinimide derivatives and their production
CO5130004A1 (en) 1-ARIL-3-ARILMETIL-1,8-NAFTIRIDIN-4 (1H) -ONAS
ES8800190A1 (en) Benzofuran and benzothiophene derivatives, their use in inhibiting mammalian leukotriene biosynthesis, and pharmaceutical compositions containing these derivatives.
HU9301084D0 (en) (1,2,4-oxadozolyl-phenoxi-alkyl)-isoxazole derivatives and their application as anti-viral agent
HU9501622D0 (en) 1,4-benzodiazepine derivatives and their use as cck-mudulators
CO5251438A1 (en) DERIVATIVES OF THE HYDROXAMIC ACID REPLACED BY ARILSULFONAMIDO, COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCEDURE FOR APPLICATION AND PREPARATION
UY24802A1 (en) NEW COMPOUNDS
WO1999062909A3 (en) Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
DE60014404D1 (en) AMINOBENZOPHENONE AS INHIBITORS OF IL-1BETA AND TNF-ALPHA
KR850008489A (en) Preparation of Cephalosporin Derivatives
DE3466532D1 (en) Bicyclooxyaryl thioureas and process for preparation
HRP20010630B1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
KR880009021A (en) Pyrazolo [3,4-d] pyrimidine derivatives, compositions and uses thereof
ATE273978T1 (en) 7-AMINOPYRIDO(2,3-D)-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF BRONCHIAL ASTHMA
EP1144393A3 (en) Heterocyclic derivatives and their use as integrin inhibitor
WO2000018741A3 (en) Pyrazole compounds as cox-2 inhibitors
ES8304995A1 (en) Cephalosporins, process for their preparation and pharmaceutical compositions containing them.
DE69838385D1 (en) ANGIOGENESIS-INHIBITING 5-SUBSTITUTED-1,2,4-THIADIAZOLYL DERIVATIVES

Legal Events

Date Code Title Description
FC Application refused